<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01872845</url>
  </required_header>
  <id_info>
    <org_study_id>4-2013-0206</org_study_id>
    <nct_id>NCT01872845</nct_id>
  </id_info>
  <brief_title>A Trial Comparing the Effect of Pravastatin and Rosuvastatin on Atherosclerosis Progression Measured by Carotid Intima Media Thickness in Patients With Coronary Artery Disease After Biolimus Eluting Stent (Nobori®) Implantation: CPR IMT</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current consensus papers recommend statin medication to reduce Low density lipoprotein (LDL)
      cholesterol level less than 100mg/dL (optional 70mg/dL) in patients with coronary artery
      disease. However, there is lack of solid evidence whether a specific kind of statin have the
      superiority against other statins in clinical outcomes. Furthermore, recent data have showed
      that several kinds of statin could have an adverse effect on glucose metabolism and increase
      the risk of development of diabetes. Carotid Intimamedia thickness (CIMT) is a surrogate
      marker of atherosclerosis to predict long term cardiovascular outcomes in not only general
      population but also patients with established coronary artery disease. Consequently, we will
      evaluate the efficacy of high dose of pravastatin on CIMT, comparing with moderate dose of
      rosuvastatin in patients with established coronary artery disease. Additionally, we will
      assess the clinical outcomes of pravastatin after percutaneous coronary intervention as well
      as adverse outcomes including insulin resistance and new onset diabetes compared with
      rosuvastatin. Our main hypothesis is that pravastatin 40mg would be non-inferior to
      rosuvastatin 20mg regarding CIMT at 1 year follow up.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of carotid intima media thickness 1 year after pravastatin or rosuvastatin treatment</measure>
    <time_frame>1 year after drug-eluting stent implantation</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">740</enrollment>
  <condition>Coronary Artery Occlusive Disease</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All study subjects will be received percutaneous coronary intervention (PCI) with Biolimus-eluting stent as index procedure at the time of enrollment After index procedure, patients will be randomly assigned to receive pravastatin 40mg or rosuvastatin 20mg in a 1:1 ratio. a&gt; Test group: Pravastatin 40mg PO daily for 1year from the day of BES implantation b&gt; Control group: Rosuvastatin 20mg PO daily for 1year from the day of BES implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pravastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All study subjects will be received percutaneous coronary intervention (PCI) with Biolimus-eluting stent as index procedure at the time of enrollment After index procedure, patients will be randomly assigned to receive pravastatin 40mg or rosuvastatin 20mg in a 1:1 ratio. a&gt; Test group: Pravastatin 40mg PO daily for 1year from the day of BES implantation b&gt; Control group: Rosuvastatin 20mg PO daily for 1year from the day of BES implantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pravastatin 40mg</intervention_name>
    <description>Pravastatin 40mg PO daily for 1year from the day of BES implantation</description>
    <arm_group_label>Pravastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Rosuvastatin 20mg PO daily for 1year from the day of BES implantation</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≥ 20 years old

          -  Patients with coronary artery disease who are candidate for coronary revascularization
             with DES implantation.

          -  Significant coronary de novo lesion (stenosis &gt; 70% by quantitative angiographic
             analysis)

          -  Patients eligible for statin treatment (initial LDL cholesterol &gt;70mg/dL or patients
             taking lipid-lowering agent)

        Exclusion Criteria:

          -  Severe hepatic dysfunction (3 times normal reference values)

          -  Pregnant women or women with potential childbearing

          -  Life expectancy &lt; 1 year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Myeong Ki Hong, MD, PhD</last_name>
    <phone>82-2-2228-8460</phone>
    <email>mkhong61@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MyeongKi Hong, MD, PhD</last_name>
      <phone>82-2-2228-8460</phone>
      <email>mkhong61@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2013</study_first_submitted>
  <study_first_submitted_qc>June 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2013</study_first_posted>
  <last_update_submitted>September 5, 2016</last_update_submitted>
  <last_update_submitted_qc>September 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Statin</keyword>
  <keyword>CIMT</keyword>
  <keyword>BES</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Pravastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

